CD38 and acute lymphoblastic leukemia: XmAb968 is another CD38 × CD3 TCE with optimized relative affinities for both CD3 and CD38, currently in a phase 1 trial recruiting patients with T cell acute lymphoblastic leukemia (T-ALL) (NCT05038644) [83], since CD38 expression in leukemic blasts of T-ALL has been found to be robust [84].